<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221221056887N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-12</date_registration>
      <primary_sponsor>Biotechnology Development Headquarters</primary_sponsor>
      <public_title>Investigating the effect of an acidophilic Lactobacillus brevis strain enriched with selenium on bedsores of ICU patients of Shahid Bahonar Medical Center, Kerman</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of an acidophilic Lactobacillus brevis strain enriched with selenium on bedsores of ICU patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68885</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After examining the patients in terms of the criteria for entering the study and obtaining informed consent, the total number of people eligible to enter the study will be divided into two equal groups of 40 people, and the placement of people in these two groups will be done by block randomization along with the blinding process. It was like this that in the randomization, people are placed in two groups randomly and completely randomly, and in order to equalize the number of people in the two groups, block randomization will be done if needed (if the total sample size at the beginning of the study for If block randomization is not available, then randomization is used by the random number table method in such a way that we divide the number of people into two groups based on the random number table, Blinding description: This study has been double-blind in that the patient himself does not know the type of capsule received, and also the treatment staff such as the clinical supervisor and project researchers such as the evaluator of the investigated factors and the outcome researcher do not know the type of capsule prescribed and only based on Capsule number 1 and 2 are prescribed and will be determined at the time of data analysis.</study_design>
      <phase>2-3</phase>
      <hc_freetext>bedsores.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: studied probiotic (probiotic capsule - containing 109 cfu of Lactobacillus isolated from dairy and edible products, which is cultured in an environment containing selenium salt to be enriched with selenium, and after laboratory confirmation of the bacteria, it is used in the study for human use - manufacturing Kerman University of Medical Sciences - Iran, which is prescribed to the patient once a day for 2 weeks, and if the patient is intubated, it is given to the patient through the NG tube, which is installed in the ward for patients with reduced level of consciousness. Intervention 2: Control group: Placebo (Placebo capsule or placebo contains 50 grams of maltodextrin made in Iran, which is prescribed to the patient once a day for 2 weeks, and if the patient is intubated, it is inserted through the NG tube in the ward for patients with reduced level of consciousness. is given to the patient).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Project data will be published without mentioning personal information and identification of study subjects

When:
Access starts from the publication of the final report

To whom:
The data that can be published is published in the form of a final report and is available to everyone

Conditions:
The data that can be published will be announced in the final report of the plan

Where to obtain:
Kerman University of Medical Sciences, Medical University Campus, Haft-Bagh Highway, Kerman, Iran

How to obtain:
After the completion of the project (1 year)

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farshid Ataollahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Qaraney St, Next to Shahid Bahonar Hospital, Upper Floor 0f Pharmacy No.2 , Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616911319</zip>
        <telephone>+98 34 3223 8942</telephone>
        <email>farshid.ataollahi@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farshid Ataollahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Qaraney St, Next to Shahid Bahonar Hospital, Upper Floor 0f Pharmacy No.2 , Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616911319</zip>
        <telephone>+98 34 3223 8942</telephone>
        <email>farshid.ataollahi@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>having bedsores (stage 1 and 2)
Not receiving other probiotics
Being hospitalized in the ICU department of Bahnar Hospital
Not having sepsis, pneumonia, other active infection and known immunodeficiency</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient was discharged from the ICU and anesthesia service of Bahnar Hospital</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L89</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pressure ulcer</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: studied probiotic (probiotic capsule - containing 109 cfu of Lactobacillus isolated from dairy and edible products, which is cultured in an environment containing selenium salt to be enriched with selenium, and after laboratory confirmation of the bacteria, it is used in the study for human use - manufacturing Kerman University of Medical Sciences - Iran, which is prescribed to the patient once a day for 2 weeks, and if the patient is intubated, it is given to the patient through the NG tube, which is installed in the ward for patients with reduced level of consciousness.</i_keyword>
      <i_keyword>Control group: Placebo (Placebo capsule or placebo contains 50 grams of maltodextrin made in Iran, which is prescribed to the patient once a day for 2 weeks, and if the patient is intubated, it is inserted through the NG tube in the ward for patients with reduced level of consciousness. is given to the patient)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bedsore. Timepoint: The entire duration of drug administration. Method of measurement: Observation and examination of the wound by the researcher (wound healing time, wound dimensions and wound stage).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Kerman University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Biotechnology Development Headquarters</source_name>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-01</approval_date>
        <contact_name>Ethics committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Jahad Blvd. Ebn Sina Avenue, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
